Farzan Clinical Research is now in cooperation with Sanofi-Aventis for Monitoring ACCESS registry in two major Iranian Heart Centers, including Tehran Heart Center and Shahid Rajai Heart Hospital.
“ACCESS – Acute Coronary Events: A Multinational survey of current management strategies” with registration number of DIREG_R_01959, is sponsored by Sanofi-Aventis Paris – France to evaluate risk stratification, current management and one year outcomes in patients with unstable angina. This study has a baseline event, studying hospitalization and discharge of the patients and two follow-ups. It is conducted in 20 developing countries.
In this study, 700 patients in the best and most famous Iranian Heart Hospitals would be recruited.
Sanofi-Aventis is a French multinational pharmaceutical company headquartered in Paris, France, the world’s fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines. It is the world’s largest producer of vaccines through its subsidiary Sanofi Pasteur. With more than 110,000 employees in a hundred countries, Sanofi-Aventis has a strong presence worldwide.
Farzan Clinical Research is the first Iranian Clinical Research Organization (CRO). Farzan Clinical Research is now an important partner for many Universities, research centers, scientific societies as well as pharmaceutical and medical device industry. Farzan Clinical Research was founded in Feb 2008 as the first Iranian registered CRO and now offers Clinical Trial Management, Clinical Trial Monitoring, Data Management, Biostatistics and Medical Writing services. Farzan Clinical Research is certified by Ministry of Health and Medical Education- Food and Drug Organization (FDA) – Islamic Republic of Iran.
